Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC)
Historical Holders from Q4 2024 to Q3 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Symbol
-
ENSC on Nasdaq
-
Shares outstanding
-
2,371,778
-
Price per share
-
$1.42
-
All holders as of 30 Sep 2025
-
Q3 2025
-
Total 13F shares
-
351,699
-
Total reported value
-
$833,709
-
% of total 13F portfolios
-
0%
-
Share change
-
+172,546
-
Value change
-
+$409,291
-
Number of holders
-
17
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Significant Owners of Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) based on Schedule 13D/G filings
As of 30 Sep 2025,
Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) has
17
institutional shareholders
filing 13F forms.
They hold
351,699 shares.
of 2,371,778
outstanding shares (15%)
.
Top 19 institutional
shareholders
own
15%
of the company.
| Filer |
Ownership |
Nb Shares |
Share Change % |
Portfolio % |
Holdings Value |
|
PERCEPTIVE ADVISORS LLC
|
3.7%
|
86,666
|
0%
|
0.01%
|
$205,398
|
|
ADAGE CAPITAL PARTNERS GP, L.L.C.
|
3.1%
|
74,711
|
0%
|
0%
|
$177,065
|
|
DRW Securities, LLC
|
2.9%
|
69,145
|
|
0.01%
|
$163,873
|
|
VANGUARD GROUP INC
|
1.5%
|
36,708
|
|
0%
|
$86,998
|
|
RENAISSANCE TECHNOLOGIES LLC
|
0.66%
|
15,574
|
|
0%
|
$36,910
|
|
CITADEL ADVISORS LLC
|
0.61%
|
14,518
|
|
0%
|
$34,408
|
|
Virtu Financial LLC
|
0.6%
|
14,222
|
|
0%
|
$34,000
|
|
GEODE CAPITAL MANAGEMENT, LLC
|
0.55%
|
13,030
|
+28%
|
0%
|
$30,880
|
|
XTX Topco Ltd
|
0.46%
|
10,957
|
|
0%
|
$25,968
|
|
TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC
|
0.44%
|
10,500
|
|
0.02%
|
$24,885
|
|
FNY Investment Advisers, LLC
|
0.13%
|
3,000
|
0%
|
0%
|
$7,000
|
|
Tower Research Capital LLC (TRC)
|
0.06%
|
1,348
|
-1.5%
|
0%
|
$3,195
|
|
UBS Group AG
|
0.03%
|
800
|
+126%
|
0%
|
$1,896
|
|
SBI Securities Co., Ltd.
|
0.02%
|
418
|
-82%
|
0%
|
$991
|
|
BlackRock, Inc.
|
0%
|
65
|
0%
|
0%
|
$154
|
|
BANK OF AMERICA CORP /DE/
|
0%
|
24
|
+26%
|
0%
|
$57
|
|
ASSETMARK, INC
|
0%
|
13
|
|
0%
|
$31
|
|
RAYMOND JAMES FINANCIAL INC
|
0%
|
0
|
-100%
|
|
$0
|
|
MORGAN STANLEY
|
0%
|
0
|
-100%
|
|
$0
|
Institutional Holders of Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) across Reporting Periods
| Period |
Reported Shares, Excl. Options
|
Value, Excl. Options
|
Value Change
|
Puts Notional Value
|
Calls Notional Value
|
Price
|
Investors
|
|
2025 Q3
|
351,699
|
$833,709
|
+$409,291
|
|
|
$2.37
|
17
|
|
2025 Q2
|
179,153
|
$398,820
|
-$449,714
|
|
|
$2.23
|
11
|
|
2025 Q1
|
353,153
|
$903,390
|
+$543,275
|
|
|
$2.56
|
9
|
|
2024 Q4
|
140,823
|
$1,145,879
|
+$1,145,879
|
|
|
$8.14
|
8
|